Welcome to our dedicated page for Nucana SEC filings (Ticker: NCNA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The NuCana plc (NCNA) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as a foreign private issuer listed on The Nasdaq Capital Market. NuCana files annual reports on Form 20-F and frequent Form 6-K current reports under the Securities Exchange Act of 1934, which together give investors detailed insight into its clinical-stage oncology business, financial position, and capital markets activity.
Through these filings, NuCana reports unaudited condensed consolidated financial statements, management’s discussion and analysis of financial condition and results of operations, and information on equity financings, warrant issuances and cancellations, and at-the-market offering activity. Form 6-K submissions also include press releases on quarterly financial results, clinical data for NUC-7738 and NUC-3373, Nasdaq listing matters, ADS ratio changes, and corporate governance updates such as leadership transitions and board resignations.
For investors analyzing NuCana’s cancer drug development programs, the filings complement press releases by documenting how clinical progress, such as the NuTide:701 and NuTide:303 studies, is reflected in research and development spending, cash resources, and risk disclosures. While NuCana’s filings do not include U.S. domestic forms like 10-K or 10-Q, the Form 20-F and associated 6-K exhibits serve similar roles in outlining key risks, forward-looking statements, and the company’s dependence on external capital to fund operations.
On Stock Titan, these SEC documents are updated as they are filed with EDGAR and can be paired with AI-powered summaries that highlight important sections, such as liquidity discussions, changes in capital structure, and descriptions of clinical milestones. Users can quickly locate specific 6-K reports tied to financial results, Nasdaq compliance updates, patent announcements, or other material events, and review how NuCana describes its ProTide technology, oncology pipeline, and anticipated cash runway within its official regulatory communications.